Therapeutically targeting the SUMOylation, ubiquitination and proteasome pathways as a novel anticancer strategy

Targeted Oncology

Volumn 5, Issue 4, 2010, Pages 281-289

  Driscoll, James J ^a   DeChowdhury, Roopa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bortezomib; NEDDylation; Proteasome; SUMOylation; Ubiquitin

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IMMUNOPROTEASOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELPHALAN; MLN 9708; NEDD8 PROTEIN; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN UBC9; PROTEINASE; SALINOSPORAMIDE A; UNCLASSIFIED DRUG;

CARCINOGENESIS; COMPLEX FORMATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; TREATMENT OUTCOME; UBIQUITINATION; UNSPECIFIED SIDE EFFECT;

HUMANS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUMOYLATION; UBIQUITIN; UBIQUITINATION;

EID: 79952900728     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-010-0165-2     Document Type: Review

References (70)

1. Hershko A, Ciechanover A, Varshavsky A (2000) Basic Medical Research Award. The ubiquitin system. Nature Med 6:1073-1081
2. Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425-479 (Pubitemid 28411135)
3. Ciechanover A (2004) The ubiquitin-proteasome proteolytic pathway. Cell 7;79(1):13-21
4. Ganoth D, Leshinsky E, Eytan E, Hershko A (1988) A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation. J Biol Chem 263:12412-12419 (Pubitemid 19000421)
5. Driscoll J, Goldberg AL (1990) The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins. J Biol Chem 265:4789-4792
6. Hochstrasser M (1995) Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7(2):215-223
7. Hochstrasser M (1996) Protein degradation or regulation: Ub the judge. Cell 84:813-815
8. Glotzer M, Murray AW, Kirschner MW (1991) Cyclin is degraded by the ubiquitin pathway. Nature 10;349(6305):132-138
9. Hoeller D, Dikic I (2009) Targeting the ubiquitin in cancer therapy. Nature 458:438-444
10. Bernassola M, Karin M, Ciechanover A, Melino G (2008) The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 14:11-21
11. Ang XI, Harper W (2005) SCF-mediated protein degradation and cell cycle control. Oncogene 24:2860-2870
12. Crews CM (2003) Feeding the machine: mechanisms of protein catalyzed degradation of ubiquitinated proteins. Curr Op Chem Biol 7:534-539
13. Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92:367-380 (Pubitemid 28093014)
14. Wolf DH, Hilt W (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochem Biophys Actas 19-31 (Pubitemid 39574965)
15. Orlowski M, Wilk S (2000) Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383:1-16
16. Hartmann-Petersen R, Gordon C (2004) Proteins interacting with the 26S proteasome. Cell Mol Life Sci 61:1589-1595 (Pubitemid 38962041)
17. Löwe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R (1995) Crystal structure of the 20S proteasome from the archæon T. acidophilum at 3.4Å resolution. Science 268:533-539
18. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R (2007) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471
19. Groll M, Bajorek M, Köhler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D (2000) A gated channel into the proteasome core particle. Nat Struct Biol 7:1062-1067
20. Driscoll J, De Chowdhury R, Burris J, Annunziata CM (2010) The expanding role of proteasome-based therapy in the treatment of hematologic malignancies. Open J Hem 1:1-4
21. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D et al (1995) The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1:221-226 (Pubitemid 129500941)
22. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R et al (2000) A gated channel into the proteasome coreparticle. Nat Struct Biol 7:1062-1067
23. Deveraux Q, Ustrell V, Pickart C, Rechsteiner M (1994) A 26S protease subunit that binds ubiquitin conjugates. J Biol Chem 269:7059-7061 (Pubitemid 24217884)
24. Hofmann K, Falquet L (2001) A ubiquitin-interacting motif conserved in components of the proteasomal and lysosomal protein degradation systems. Trends Biochem Sci 26:347-350 (Pubitemid 32530646)
25. Holzl H, Kapelari B, Kellermann J, Seemuller E, Sumegi M, Udvardy A et al (2000) The regulatory complex of Drosophila melanogaster 26S proteasomes. Subunit composition and localization of a deubiquitylating enzyme. J Cell Biol 150:119-130
26. Li T, Naqvi NI, Yang H, Teo TS (2000) Identification of a 26S proteasome-associated UCH in fission yeast. Biochem Biophys Res Commun 272:270-275 (Pubitemid 30444933)
27. Wilkinson CR, Wallace M, Seeger M, Dubiel W, Gordon C (2000) Mts4, a non-ATPase subunit of the 26S protease in fission yeast, is essential for mitosis and interacts directly with the ATPase subunit Mts2. J Biol Chem 272:25768-25777 (Pubitemid 27438897)
28. Verma R, Aravind L, Oania R, McDonald WH, Yates JR III, Koonin EV et al (2002) Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 298:611-615 (Pubitemid 35215317)
29. Wilkinson CR, Ferrell K, Penney M, Wallace M, Dubiel W, Gordon C (2000) Analysis of a gene encoding Rpn10 of the fission yeast proteasome reveals that the polyubiquitinbinding site of this subunit is essential when Rpn12/Mts3 activity is compromised. J Biol Chem 275:15182-15192 (Pubitemid 30337242)
30. Hendil KB, Hartmann-Petersen R, Tanaka K (2002) 26S proteasomes function as stable entities. J Mol Biol 315:627-636 (Pubitemid 34729314)
31. Glickman MH, Rubin DM, Coux O, Wefes I, Pfeifer G, Cjeka Z et al (1998) A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3. Cell 94:615-623 (Pubitemid 28427580)
32. Kapelari B, Bech-Otschir D, Hegerl R, Schade R, Dumdey R, Dubiel W (2000) Electron microscopy and subunit-subunit interaction studies reveal a first architecture of COP9 signalosome. J Mol Biol 300:1169-1178
33. Leggett DS, Hanna J, Borodovsky A, Crosas B, Schmidt M, Baker RT et al (2002) Multiple associated proteins regulate proteasome structure and function. Mol Cell 10:495-507 (Pubitemid 35284170)
34. Adams J (2002) Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 8(4 Suppl):S49-S54
35. Hideshima T, Richardson P, Chauhan D et al (2002) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61(7):3071-3076
36. Mitsiades N, Mitsiades CS, Poulaki V et al (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99(22):14374-14379 (Pubitemid 35257679)
37. Carvalho P, Goder V, Rapoport TA (2006) Distinct ubiquitinligase complexes define convergent pathways for the degradation of ER proteins. Cell 126:361-373 (Pubitemid 44092963)
38. Raasi S, Wolf DH (2007) Ubiquitin receptors and ERAD: a network of pathways to the proteasome. Semin Cell Dev Biol 18:780-791 (Pubitemid 350138450)
39. Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6):508-515
40. Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609-2617 (Pubitemid 36741588)
41. Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487-2498 (Pubitemid 41007864)
42. San Miguel JF, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906-917
43. Richardson PG, Briemberg H, Jagannath S et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113-3120 (Pubitemid 46638949)
44. Kupperman et al (2010) Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Can Res 70 (5):1970-1980
45. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al (2009) An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458:732-736
46. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22:159-180
47. Johnson ES (2004) Protein modification by SUMO. Annu Rev Biochem 73:355-382
48. Melchior F, Schergaut M, Pichler A (2008) SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem Sci 28:612-618 (Pubitemid 38352808)
49. Kamitani T, Kito K, Nguyen HP, Yeh ET (1997) Characterization of NEDD8, a developmentally down-regulated ubiquitin- like protein. J Biol Chem 272:28557-28562 (Pubitemid 27517807)
50. Muller S, Ledl A, Schmidt D (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene 23:1998-2008 (Pubitemid 38496729)
51. Seeler JS, Dejean A (2003) Nuclear and unclear functions of SUMO. Nat Rev Mol Cell Biol 4:690-699
52. Ulrich HD (2008) The fast-growing business of SUMO chains. Mol Cell 32:301-305
53. Geoffroy MC, Hay RT (2009) An additional role for SUMO in ubiquitin-mediated proteolysis. Nature 10:364-368
54. Tatham MH et al (2008) RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nature Cell Biol 10:538-546 (Pubitemid 351627373)
55. Driscoll J, Pelluru D, Lefkimmiatis K et al (2010) The SUMOylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 115:2827-2834
56. Mo Y-Y, Moschos S (2005) Targeting Ubc9 for cancer therapy. Exp Opin Therap Targets 9:1203-1216 (Pubitemid 41762874)
57. Wu F, Zhu S, Ding Y, Beck WT, Mo YY (2009) MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 1;15(5):1550-1557
58. Sun H, Lverson JD, Hunter T (2007) Conserved function of RNF4 family proteins in eukaryotes: targeting a ubiquitin ligase to SUMOylated proteins. EMBO J 26:4102-4112 (Pubitemid 47462098)
59. Kosoy A, Calonge TM, Outwin EA, O'Connell MJ (2007) Fission yeast RNF4 homologs are required for DNA repair. J Biol Chem 282:20388-20394 (Pubitemid 47099981)
60. Prudden J, Pebernard S, Raffa G, Slavin DA, Perry JJ, Tainer JA, McGowan CH, Boddy MN (2007) SUMO-targeted ubiquitin ligases in genome stability. EMBO J 26:4089-4101 (Pubitemid 47462097)
61. Uzunova K, Gottsche K, Miteva M,Weisshaar SR, Glanemann C, Schnellhardt M, Niessen M, Scheel H, Hofmann K, Johnson ES, Praefcke GJ, Dohmen RJ (2007) Ubiquitin-dependent proteolytic control of SUMO conjugates. J Biol Chem 282:34167-34175 (Pubitemid 350159437)
62. Xie Y, Kerscher O, Kroetz MB, McConchie HF, Sung P, Hochstrasser M (2007) The yeast Hex3•Slx8 heterodimer is a ubiquitin ligase stimulated by substrate sumoylation. J Biol Chem 282:34176-34184 (Pubitemid 350159438)
63. Weissman AM (2001) Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2:169-178
64. Deshaies RJ (1999) SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 15:435-467
65. Kloetzel P (2001) Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2:179-188
66. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, Grunebach F, Brossart P (2006) Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108:551-558 (Pubitemid 44061355)
67. Tseng CW, Monie A, Wu CY, Huang B, Wang MC, Hung CF, Wu TC (2008) Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med 86:899-908
68. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B et al (2009) Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 111:1309-1317 (Pubitemid 351213417)
69. Bakker A, Phillips J, Figdor C, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, γδT cells, and antigen-specific CTL. J Immunol 160:5239-5245 (Pubitemid 28267808)
70. Lundqvist A, Su S, Rao S, Childs R (2010) Cutting edge: bortezomib-treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells. J Immunol 184(3):1139-1142